We, therefore, used in vitro models to investigate the potential impact of hormone-independent actions of ER on the survival or proliferation of hormone-sensitive breast cancer cells and the related mechanisms under conditions that mimic hormonal adjuvant therapy, that is, estrogen-depletion and tamoxifen treatment. Here, ESR1 is linked to breast cancer.